Biocon enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


56,848	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3,106	3,106	3,674	1,549	2,650
2,590	2,590	6,069	5,491	4,622
14,825	14,825	17,756	15,730	17,771
71,157	—	—	—	—
11,718	11,718	14,081	14,180	15,121
₹438.97	—	—	—	—

51,446	51,446	45,468	41,004	40,260
28.8%	28.8%	39.1%	38.4%	44.1%
0.21×	—	—	—	—

4.11×	—	—	—	—
20.12×	—	—	—	—
47.84×	—	—	—	—
864.60×	—	—	—	—
17,321	16,927	15,262	14,756	11,174
3,536	3,455	3,166	3,299	2,512
1,487	1,499	1,479	1,730	1,399
—	1,994	4,061	2,954	1,853
82.3	82.3	1,718	1,022	126
—	−70.5	1,564	903	10.2
—	1,912	2,343	1,932	1,726

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BIOCON₹350.70

Biocon Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY SYNGENE MANKIND GLENMARK LAURUSLABS ALKEM LUPINMcap ₹56,848 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	56,848.5
- Cash, Equiv & ST Investments	2,650.0	1,549.2	3,674.4	3,106.3	3,106.3
+ Minority Interest	4,621.9	5,491.1	6,068.5	2,589.7	2,589.7
+ Total Debt	17,770.7	15,729.6	17,755.5	14,824.7	14,824.7
Enterprise Value	—	—	—	—	71,156.6
Net Debt (memo)	15,120.7	14,180.4	14,081.1	11,718.4	11,718.4
EV per Share	—	—	—	—	438.97

Total Capital	40,259.5	41,004.4	45,468.0	51,446.2	51,446.2
Total Debt/Total Capital	44.14	38.36	39.05	28.82	28.82
Total Debt/EV	—	—	—	—	0.21

EV/Sales	—	—	—	—	4.11
EV/EBITDA	—	—	—	—	20.12
EV/EBIT	—	—	—	—	47.84
EV/Free Cash Flow	—	—	—	—	864.60
Reference Items — Trailing FY Values
Sales	11,174.2	14,755.7	15,261.7	16,927.0	17,321.1
EBITDA	2,511.7	3,298.7	3,166.3	3,455.3	3,536.4
EBIT	1,398.6	1,729.9	1,479.3	1,498.6	1,487.3
Operating Cash Flow	1,852.5	2,953.9	4,061.2	1,994.0	—
Free Cash Flow	126.2	1,022.3	1,717.9	82.3	82.3
FCFF (free cash flow to the firm)	10.2	902.6	1,564.2	-70.5	—
Capital Expenditure	1,726.3	1,931.6	2,343.3	1,911.7	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.